Amgen Leads Investment In SiteOne Therapeutics

Thousand Oaks-based Amgen is the lead investor in a round for San Francisco- and Bozeman, Montana-based SiteOne Therapeutics, SiteOne said on Friday. SiteOne said it raised $15M in a Series B funding round, which was led b Amgen, and also included Next Frontier Capital and insiders. SiteOne is developing no-opioid analgesics, aimed at treating chronic pain without causing addiction. More information »